CRISPR Therapeutics AG Common Shares logo

CRISPR Therapeutics AG Common Shares (CRSP) Technical Analysis

$48.552.02%

Market is closed - opens 7 PM, 21 May 2026

Insights

  • CRISPR Therapeutics AG Common Shares is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
  • Based on analysis of the Oscillators technical indicator, the current market trend for CRISPR Therapeutics AG Common Shares stock suggests that it is range bound and no decision can be made based on this information
  • Based on analysis of the Moving Averages technical indicator, CRISPR Therapeutics AG Common Shares stock is in a downtrend↘️
  • Based on analysis of the Pivot Points, the current market trend for CRISPR Therapeutics AG Common Shares stock suggests that it is a good time to sell or bad time to initiate a fresh position

Analysis Summary

Oscillators

Sell

Neutral

Buy

Moving Averages

Sell

Neutral

Buy

Pivots

Sell

Neutral

Buy

Oscillators

Name

Value

Action

Relative Strength Index
39.18
Neutral
Stochastic
7.25, 5.11
Buy
Ultimate Oscillator
32.38
Neutral
Stochastic Relative Strength Index
0.93, 7.28
Neutral
Moving Average Convergence Divergence
-0.84, -0.14
Neutral

Moving Averages

Simple Moving Average

Period (Days)

Value

Action

10
51.69
Sell
20
52.05
Buy
50
51.07
Sell

Exponential Moving Average

Period (Days)

Value

Action

10
50.64
Sell
20
51.6
Sell
50
52.16
Sell

Volume Weighted Moving Average

Period (Days)

Value

Action

10
51.85
Sell
20
52.11
Sell
50
51.29
Sell

Double Exponential Moving Average

Period (Days)

Value

Action

10
49.05
Sell
20
50.74
Sell
50
51.41
Buy

Triple Exponential Moving Average

Period (Days)

Value

Action

10
48.02
Sell
20
49.7
Sell
50
51.64
Buy

Pivot

Pivot

Value

Resistance L3
51.75
Resistance L2
50.91
Resistance L1
49.74
Pivot Point
48.9
Support L1
47.73
Support L2
46.89
Support L3
45.72

*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.